Akèy › Ipòparatiwoïdism
Etid klinik pou Ipòparatiwoïdism ap rekrite nan Etazini
8 etid pou Ipòparatiwoïdism ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07081997A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07699471Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07805356A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
Ap rekriteEtid obsèvasyon
Laj 18 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT07264634Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou May 7, 2026 · NCT07083557A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Ap rekriteEtid obsèvasyon
Laj 15 a 50 · Fanm · Mizajou Mar 2, 2026 · NCT07345494Parathyroid Allotransplant for Treatment of Hypoparathyroidism
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Feb 27, 2026 · NCT06961071Hypoparathyroidism Natural History Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Dec 16, 2025 · NCT05793853Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.